Marie Menard

Marie Menard

Auto-generated profile, based on publicly available information

Marie Menard

University of California 1 Department of Neurology San Francisco, CA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JJJingjing Jiang
Jingjing Jiang
LJLingyan Jiang
Lingyan Jiang
BMBenjamin J. Maldonato
Benjamin J. Maldonato
YWYingyun Wang
Yingyun Wang
MHMatthew Holderfield
Matthew Holderfield
MSMallika Singh
Mallika Singh
RAS-driven cancers comprise up to 30% of human cancers. RMC-6236 is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential for the aforementioned unmet medical need. RMC-6236 exhibited potent anticancer activity across RAS-addicted cell lines, particularly those harboring mutations at codon 12 of KRAS. Notably, oral administration of RMC-6236 was tolerated in vivo and drove profound tumor regressions across multiple tumor types in a mouse clinical trial with KRASG12X xenograft models. Translational PK/efficacy and PK/PD modeling predicted that daily doses of 100 mg and 300 mg would achieve tumor control and objective responses, respectively, in patients with RAS-driven tumors. Consistent with this, we describe here objective responses in two patients (at 300 mg daily) with advanced KRASG12X lung and pancreatic adenocarcinoma, respectively, demonstrating the initial activity of RMC-6236 in an ongoing phase I/Ib clinical trial (NCT05379985). Significance: The discovery of RMC-6236 enables the first-ever therapeutic evaluation of targeted and concurrent inhibition of canonical mutant and wild-type RAS-GTP in RAS-driven cancers. We demonstrate that broad-spectrum RAS-GTP inhibition is tolerable at exposures that induce profound tumor regressions in preclinical models of, and in patients with, such tumors.

7 March 2025 in Cancer Discovery
Verified
Journal Article
Open access
MOMargo Orlen
Margo Orlen
WVWilliam P. Vostrejs
William P. Vostrejs
RSRina Sor
Rina Sor
JMJayne C. McDevitt
Jayne C. McDevitt
SKSamantha B. Kemp
Samantha B. Kemp
BSBen Z. Stanger
Ben Z. Stanger
Activating mutations in KRAS drive tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), promoting tumor cell proliferation and contributing to an immunosuppressive tumor microenvironment, rendering PDAC tumors insensitive to immunotherapy. RAS(ON) multi-selective inhibitors, such as daraxonrasib (RMC-6236) and RMC-7977, target the active state of RAS, with potent antitumor activity in PDAC murine models. In this study, we report that RAS(ON) multi-selective inhibition led to rapid and profound PDAC regressions in immunocompetent mice, decreasing myeloid cells and increasing T cells and macrophages in the tumor microenvironment. The depth and duration of tumor regression depended on T cells and conventional dendritic cells. Moreover, the combination of RAS(ON) multi-selective inhibitors with immunotherapy conferred deeper and more durable tumor regressions, including complete responses not seen with either treatment alone. In summary, concurrent inhibition of mutant and wild-type RAS is active in concert with T-cell immunotherapy, revealing RAS(ON) multi-selective inhibitors as a potential therapeutic immuno-sensitizing strategy in PDAC. Significance: RAS(ON) multi-selective inhibitors enhance antitumor immunity in preclinical models of PDAC, resulting in deeper and more durable responses when combined with immunotherapy. These findings support the clinical evaluation of immune-based strategies that may prolong the response to RAS inhibitor therapies as well as overcome issues of therapeutic resistance to inhibitors alone. See related commentary by Lasse Opsahl and Pasca di Magliano, p. 1537

4 April 2023 in Cancer Research
Verified
Journal Article
Closed access
MMMarie J. Menard
Marie J. Menard
CCChristopher W.K. Chow
Christopher W.K. Chow
KCKevin Chen
Kevin Chen
CBCristina Blaj
Cristina Blaj
NSNataliya Tovbis Shifrin
Nataliya Tovbis Shifrin
EQElsa Quintana
Elsa Quintana
Major epithelial tumors harboring the cancer driver KRASG12D, the most common oncogenic KRAS mutation1, remain an outstanding unmet medical need. While oncogenic RAS primarily promotes tumor progression through sustained cellular proliferation, there is also increasing evidence that it adversely shapes the tumor microenvironment (TME) through the induction of immuno-suppressive cytokines2, downregulation of MHCI, and modulation of checkpoint proteins3. KRASG12D oncoproteins can be selectively targeted with the covalent tri-complex RAS(ON) inhibitor, RMC-9805, which has been shown to inhibit RAS signaling in KRASG12D mutant cancer cells and induce apoptosis. RMC-9805 also decreased the secretion of immunosuppressive cytokines by KRASG12D tumor cells, while promoting the secretion of lymphocyte-recruiting factors. Oral administration of RMC-9805 drove durable complete responses and synergized with anti-PD-1 in an immune-infiltrated colorectal KRASG12D mutant model. Re-challenge experiments further demonstrated that RMC-9805 induced immunological memory. The activity of RMC-9805 was also assessed in an orthotopic, immune-evasive, GEMM-derived preclinical model for PDAC, where it induced a profound and sustained inhibition of RAS signaling, driving initial tumor regressions and significantly prolonging survival. Tumors treated with RMC-9805 in vivo showed significant transformation of the TME in favor of anti-tumor immunity, with an increase in T cell infiltration and decrease in immunosuppressive myeloid cells, including M2-like macrophages and MDSCs. RMC-9805 also modulated expression of cancer cell surface proteins, notably decreasing expression of immune checkpoint molecules while significantly increasing MHC-I expression. TCR sequencing of T cells from tumors and blood harvested from treated mice revealed a significant increase in T cell diversity, as well as an increase in the number of shared TCR clones among all KRASG12D(ON) inhibitor-treated samples, suggesting cancer-associated antigen recognition. Overall, in these preclinical experiments, RMC-9805 exhibited direct anti-tumor effects and indirectly transformed the TME through inhibition of cancer cell-intrinsic KRASG12D oncogenic signaling. The increased antigen presentation, recognition, and T cell infiltration induced by inhibition of mutant KRAS may permit a more favorable environment for immune-directed ‘companion’ therapies, such as checkpoint inhibitors, cellular therapies, and/or vaccines. [1] Timar, J. et al, 2020 [2] Hamarsheh, S. et al, 2020 [3] Sumimoto, H. et al, 2016 Citation Format: Marie J. Menard, Christopher Chow, Kevin Chen, Cristina Blaj, Nataliya Tovbis Shifrin, Haley Courtney, Nicole M. Nasholm, Anna Pham, Alice Kumamoto, Swetha Ganesh, James W. Evans, Lindsey Lawrence, Brian Vonmelchert, Amy C. Kwok-Parkhill, Jingjing Jiang, John E. Knox, Jacqueline Smith, Elsa Quintana. RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3475.

14 July 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
MMMarie Ménard
Marie Ménard
HYHiroyuki Yoda
Hiroyuki Yoda
NNNicole Nasholm
Nicole Nasholm
MBMegumi J. Barata
Megumi J. Barata
LWLinyu Wang
Linyu Wang
WWWilliam A. Weiss
William A. Weiss
Neuroblastomas are highly heterogeneous tumors originating from neural crest-derived cells destined to form the sympathetic nervous system. Nearly half of high-risk tumors present with amplification of the MYCN proto-oncogene. Here, we describe a Mycn-driven, transplantable, non-germline, genetically engineered mouse model (Mycn-nGEMM). Mycn-nGEMM tumors recapitulate the immune-evasive, macrophage-rich tumor microenvironment of high-risk, MYCN-amplified human neuroblastoma. Treatment of tumor-bearing mice with anti–PD-L1, but not anti-PD-1 or anti-CTLA-4, inhibited tumor growth, profoundly remodeling the tumor microenvironment by depleting anti-inflammatory macrophages and increasing T cell infiltration. Surprisingly, while tumor cells showed low expression of PD-L1, anti-inflammatory macrophages from both murine and human neuroblastoma expressed PD-L1. We identified cytokines, including macrophage migration inhibitory factor, secreted by the Mycn-nGEMM cancer cells that drive expression of PD-L1 on macrophages. Combining anti–PD-L1 with CD40 agonist antibodies further improved survival in Mycn-nGEMM mice, demonstrating the potential for myeloid-targeting immunotherapies to overcome inhibitory barriers in immune-evasive neuroblastoma.

4 June 2024
Verified
Other
Open access
JJJingjing Jiang
Jingjing Jiang
LJLingyan Jiang
Lingyan Jiang
BMBenjamin J. Maldonato
Benjamin J. Maldonato
YWYingyun Wang
Yingyun Wang
MHMatthew Holderfield
Matthew Holderfield
MSMallika Singh
Mallika Singh
Supplementary Table S8 shows all parameter estimates for PK/Efficacy and PK/PD modeling.

4 June 2024
Verified
Other
Open access
JJJingjing Jiang
Jingjing Jiang
LJLingyan Jiang
Lingyan Jiang
BMBenjamin J. Maldonato
Benjamin J. Maldonato
YWYingyun Wang
Yingyun Wang
MHMatthew Holderfield
Matthew Holderfield
MSMallika Singh
Mallika Singh
Supplementary Table S1 shows information on the PRISM cell set comprised of 845 cell lines representing more than 45 lineages.